Subtopic Deep Dive
C-Peptide as Biomarker of Residual Beta-Cell Function
Research Guide
What is C-Peptide as Biomarker of Residual Beta-Cell Function?
C-peptide serves as a biomarker measuring residual beta-cell function by quantifying endogenous insulin secretion in diabetes patients.
Stimulated C-peptide assays track honeymoon phase duration in type 1 diabetes (T1D). Low autoantibody titers and avoidance of rapid metabolic decompensation predict prolonged residual function (Chiang et al., 2014). Over 10 papers in provided lists reference C-peptide in T1D standards and interventions.
Why It Matters
C-peptide monitoring evaluates interventions like teplizumab, which delayed T1D onset by preserving beta-cell function (Herold et al., 2019). In islet transplantation trials, stimulated C-peptide levels above 0.3 nmol/L post-meal reduced severe hypoglycemia (Hering et al., 2016). ADA standards recommend mixed-meal stimulated C-peptide for assessing therapeutic preservation of insulin secretion (ElSayed et al., 2022). This shifts T1D management toward partial endogenous insulin paradigms, reducing exogenous insulin needs.
Key Research Challenges
Standardizing Stimulation Protocols
Variability in mixed-meal vs. glucagon stimulation affects C-peptide comparability across studies (ElSayed et al., 2022). Thresholds for clinically meaningful residual function remain debated (Chiang et al., 2014). Over 2000 citations in ADA guidelines highlight protocol inconsistencies.
Predicting Honeymoon Duration
Predictors like low autoantibody titers correlate imperfectly with C-peptide trajectories (Herold et al., 2019). Rapid metabolic decompensation accelerates beta-cell loss, complicating early intervention timing. Coppieters et al. (2012) link autoreactive T cells to progression post-diagnosis.
Quantifying Intervention Efficacy
Teplizumab increases C-peptide area-under-curve, but long-term sustainability is unclear (Herold et al., 2019). Islet transplants achieve C-peptide independence in some, but graft function wanes (Hering et al., 2016). Autoimmune mechanisms hinder durable preservation (Coppieters et al., 2012).
Essential Papers
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda et al. · 2022 · Diabetes Care · 2.2K citations
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, gene...
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Kevan C. Herold, Brian N. Bundy, S. Alice Long et al. · 2019 · New England Journal of Medicine · 1.0K citations
Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Jane L. Chiang, M. Sue Kirkman, Lori M. Laffel et al. · 2014 · Diabetes Care · 947 citations
Type 1 diabetes is characterized by an immune-mediated depletion of β-cells that results in lifelong dependence on exogenous insulin. While both type 1 and type 2 diabetes result in hyperglycemia, ...
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients
Ken Coppieters, Francesco Dotta, Natalie Amirian et al. · 2012 · The Journal of Experimental Medicine · 650 citations
A direct association of islet-autoreactive T cells with β cell destruction in human pancreatic islets from type 1 diabetes (T1D) patients has never been demonstrated, and little is known about dise...
Pathophysiology of diabetes: An overview
Syed Sameer Aga, Mujeeb Zafar Banday, Saniya Nissar · 2020 · Avicenna Journal of Medicine · 628 citations
Diabetes mellitus is a chronic heterogeneous metabolic disorder with complex pathogenesis. It is characterized by elevated blood glucose levels or hyperglycemia, which results from abnormalities in...
Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Bernhard J. Hering, William R. Clarke, Nancy D. Bridges et al. · 2016 · Diabetes Care · 626 citations
OBJECTIVE Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effe...
The Role of Oxidative Stress and Hypoxia in Pancreatic Beta-Cell Dysfunction in Diabetes Mellitus
Philipp A. Gerber, Guy A. Rutter · 2016 · Antioxidants and Redox Signaling · 620 citations
Loss of normal beta-cell function, rather than total mass, is increasingly considered to be the major driver for impaired insulin secretion in diabetes. Better understanding of the role of oxidativ...
Reading Guide
Foundational Papers
Start with Chiang et al. (2014, 947 citations) for T1D lifespan C-peptide role; then Coppieters et al. (2012, 650 citations) on autoreactive T cells destroying beta-cells.
Recent Advances
ElSayed et al. (2022, 2190 citations) for updated ADA standards; Herold et al. (2019, 1019 citations) on teplizumab preserving C-peptide.
Core Methods
Mixed-meal stimulation assays (ElSayed 2022); AUC calculation of C-peptide response (Herold 2019); HLA genotyping for susceptibility (Nejentsev 2007).
How PapersFlow Helps You Research C-Peptide as Biomarker of Residual Beta-Cell Function
Discover & Search
Research Agent uses searchPapers with query 'C-peptide stimulated assay beta-cell function T1D' to find ElSayed et al. (2022), then citationGraph reveals 2190 downstream citations on ADA standards, and findSimilarPapers uncovers Herold et al. (2019) teplizumab trial.
Analyze & Verify
Analysis Agent applies readPaperContent to extract C-peptide thresholds from Chiang et al. (2014), verifies claims via verifyResponse (CoVe) against ADA guidelines, and runPythonAnalysis plots stimulated C-peptide trajectories from trial data using pandas for statistical significance (p<0.05). GRADE grading scores intervention evidence as moderate for honeymoon extension.
Synthesize & Write
Synthesis Agent detects gaps in long-term C-peptide data post-teplizumab via gap detection, flags contradictions between HLA genetics and residual function (Nejentsev et al., 2007), and Writing Agent uses latexEditText, latexSyncCitations for Herold et al. (2019), and latexCompile to generate review sections with exportMermaid for beta-cell decline flowcharts.
Use Cases
"Extract C-peptide data from teplizumab trial and plot mean trajectories"
Research Agent → searchPapers 'Herold teplizumab C-peptide' → Analysis Agent → readPaperContent → runPythonAnalysis (pandas plot AUC vs time) → matplotlib figure of preserved function vs placebo.
"Draft LaTeX review on C-peptide in ADA T1D standards"
Synthesis Agent → gap detection on ElSayed 2022 → Writing Agent → latexEditText 'stimulated C-peptide protocols' → latexSyncCitations (Chiang 2014) → latexCompile → PDF with honeymoon phase diagram.
"Find code for analyzing C-peptide assay statistics from diabetes papers"
Research Agent → paperExtractUrls on Hering 2016 → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (NumPy stats on transplant C-peptide levels) → CSV export of p-values.
Automated Workflows
Deep Research workflow scans 50+ OpenAlex papers on 'stimulated C-peptide T1D honeymoon', structures report with GRADE-scored sections on predictors from Herold et al. (2019). DeepScan applies 7-step CoVe chain: searchPapers → readPaperContent (ElSayed 2022) → verifyResponse → contradiction flagging vs Chiang 2014. Theorizer generates hypotheses linking HLA-B susceptibility (Nejentsev 2007) to C-peptide decline models.
Frequently Asked Questions
What defines C-peptide as a beta-cell biomarker?
C-peptide is co-secreted equimolar to insulin, directly measuring endogenous secretion without exogenous interference (ElSayed et al., 2022).
What stimulation methods assess residual function?
ADA recommends mixed-meal stimulated C-peptide; thresholds >0.2 nmol/L indicate viable beta-cells (Chiang et al., 2014).
Which papers establish clinical standards?
ElSayed et al. (2022, 2190 citations) and Chiang et al. (2014, 947 citations) define ADA protocols for T1D monitoring.
What open problems persist?
Long-term C-peptide sustainability post-intervention like teplizumab; optimal predictors beyond autoantibodies (Herold et al., 2019).
Research Diabetes and associated disorders with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching C-Peptide as Biomarker of Residual Beta-Cell Function with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers
Part of the Diabetes and associated disorders Research Guide